NICE Technology Appraisals About Medicines: Southend University

Southend University Hospital NHS Foundation Trust Formulary Adherence Checklist for NICE Technology Appraisals About Medicines

East and South East England

Specialist Pharmacy Services

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. Version 5.0 May 1st 2014. Last Updated 08 May 2014

All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS. By Simon Worrall

Technology appraisal (TA) Titles are hyperlinks to full guidance

Date of TA

Release

Availability of medicine for NHS patients with

this medical condition, as indicated by NICEYes

(mark 'x' if

applicable)

N/A

(mark 'x' if

applicable)

Date of local

decision

(DD/MM/YYYY

)

Time to

implement

(days)

Notes (e.g. rationale, method of making available)

2014-15

Multiple myeloma - bortezomib (induction

therapy) (TA311)

30/04/2014 Bortezomib - an option, in combination with

dexamethasone, or with dexamethasone and

thalidomide, for the induction treatment of adults with

previously untreated multiple myeloma, who are eligible

for high-dose chemotherapy with haematopoietic stem

cell transplantation.

x

07/05/2014 7

Lung cancer (non small cell, EGFR mutation

positive) - afatinib (TA310)

30/04/2014 Afatinib - an option for adults with locally advanced or

metastatic non-small-cell lung cancer only if they have

the EGFR-TK mutation and have not had an EGFR-TK

inhibitor previously and the drug is provided at the

discount agreed in the patient access scheme.

x

07/05/2014 7

Lung cancer (non small cell, non squamous) -

pemetrexed (TA309)

30/04/2014 Pemetrexed - not recommended as maintenance

treatment for locally advanced or metastatic non-

squamous non-small-cell lung cancer in people whose

disease has not progressed immediately following

induction therapy with pemetrexed and cisplatin.

x

07/05/2014 7 available via CDF

3 0

% "Yes" % "N/A" _Average

implement time

(days)

Adherence statistics for 2014-15 100% 0% 7

Adherence of local formulary to NICE

http://guidance.nice.org.uk/TA311






Formulary Adherence Checklist for NICE Technology Appraisals About Medicines

East and South East England


This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.

All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.


Date of TA

Release

Availability of medicine for NHS patients with this

medical condition, as indicated by NICEYes

(mark 'x' if

applicable)

N/A

(mark 'x' if

applicable)

Date of local

decision

(DD/MM/YYYY

)

Time to

implement

(days)


2013-14

Vasculitis (anti-neutrophil cytoplasmic antibody-

associated) - rituximab (with glucocorticoids)

(TA308)

31/03/2014 Rituximab - recommended as an option with

glucocorticoids for adults with anti-neutrophil

cytoplasmic antibody-associated vasculitis only if further

treatment with cyclophosphamide would exceed the

maximum cumulative cyclophosphamide dose or

cyclophosphamide is contraindicated or not tolerated or

they want to have children and treatment with

cyclophosphamide may materially affect their fertility or

the disease has stayed active or progressed despite a

course of cyclophosphamide lasting 3 to 6 months or the

person has had uroepithelial malignancy.

x

01/04/2014 1

Colorectal cancer (metastatic) - aflibercept

(TA307)

31/03/2014 Aflibercept - not recommended in combination with

irinotecan and fluorouracil-based therapy for metastatic

colorectal cancer that is resistant to or has progressed

after chemotherapy that includes oxaliplatin.x

31/03/2014 0 will not be using locally

Lymphoma (non Hodgkin's, relapsed,

refractory) - pixantrone monotherapy (TA306)

28/02/2014 Pixantrone – recommended as a possible monotherapy

for multiply relapsed or refractory aggressive disease if

patients: have previously been treated with rituximab

and they are receiving 3rd or 4th-line treatment and the

drug is provided at the discount agreed in the patient

access scheme.

x

03/03/2014 3

Macular oedema (central retinal vein occlusion) -

aflibercept solution for injection (TA305)

28/02/2014 Aflibercept – recommended as an option for visual

impairment caused by macular oedema secondary to

central retinal vein occlusion only if the manufacturer

provides it with the discount agreed in the patient

access scheme.

x

05/03/2014 5

Multiple sclerosis (relapsing) - teriflunomide

(TA303)

31/01/2014 Teriflunomide – recommended as a possible treatment

under a patient access scheme for active relapsing-

remitting MS that isn’t highly active or rapidly evolving.x

31/01/2014 0



















Juvenile idiopathic arthritis (systemic) -

canakinumab (terminated appraisal) (TA302)

29/11/2013 Canakinumab – unable to recommend NHS use

because no evidence submission was received from the

manufacturer.

x29/11/2013 0 will not be using locally

Fluocinolone acetonide intravitreal implant for

treating chronic diabetic macular oedema after

an inadequate response to prior therapy (rev

271) (TA301)

29/11/2013 Fluocinolone acetonide intravitreal implant –

recommended as an option for treating chronic diabetic

macular oedema that is insufficiently responsive to

available therapies only if the implant is to be used in an

eye with an intraocular (pseudophakic) lens and as part

of a patient access scheme.

x

28/02/2014 91

Hepatitis C (children and young people) -

peginterferon alfa and ribavirin (TA300)

29/11/2013 Peginterferon alfa plus ribavirin – recommended,

within its marketing authorisation, as an option for

treating chronic hepatitis C in children and young

people.

x

29/11/2013 0 likely to used only following recommendation from

tertiary centre

Leukaemia (chronic myeloid) - bosutinib

(TA299)

29/11/2013 Bosutinib – not recommended for previously treated

Philadelphia-chromosome-positive chronic myeloid

leukaemia.

x


Choroidal neovascularisation associated with

pathological myopia - ranibizumab (TA298)

29/11/2013 Ranibizumab – recommended as an option for treating

visual impairment due to choroidal neovascularisation

secondary to pathological myopia as part of a patient

access scheme.

x

13/12/2013 14

Vitreomacular traction - ocriplasmin (TA297) 31/10/2013 Ocriplasmin – a recommended option if an epiretinal

membrane is not present and macular hole is of

specified size and type, and/or symptoms are severe.x

20/11/2013 20

Lung cancer (non-small-cell, Anaplastic-

Lymphoma-Kinase positive, previously treated) -

crizotinib (TA296)

30/09/2013 Crizotinib – not recommend for this cancer if it is ‘ALK-

positive’ and has been treated before. x


Breast cancer (HER2 negative, oestrogen

receptor positive, locally advanced or

metastatic) - everolimus (with an aromatase

inhibitor) (TA295)

31/08/2013 Everolimus with exemestane – not recommended for

postmenopausal women with breast cancer that is HER2

negative and hormone-receptor positive, and that has

recurred or worsened after a non-steroidal aromatase

inhibitor.

x


Macular degeneration (wet age-related) -

aflibercept (1st line) (TA294)

30/07/2013 Aflibercept – only recommended as an option if used

according to TA155 for ranibizumab as part of a patient

access scheme.

x02/10/2013 64

Thrombocytopenic purpura - eltrombopag

(TA293)

30/07/2013 Eltrombopag – for chronic immune (idiopathic)

thrombocytopenic purpura (ITP) post-splenectomy (or if

splenectomy contra-indicated). A recommended option

when refractory to standard therapies, or in severe

disease needing frequent rescue therapy as part of a

patient access scheme.

x

30/07/2013 0

Bipolar disorder (children) - aripiprazole

(TA292)

30/07/2013 Aripiprazole – Recommended as possible treatment (for

up to 12 weeks) for moderate to severe manic episodes

in young people aged 13 and older with bipolar I

disorder.

x

30/07/2013 0 will not be initiating locally (unless under the

recommendation of a mental health specialist )

Gout (tophaceous, severe debilitating, chronic) -

pegloticase (TA291)

30/06/2013 Pegloticase – not recommended for people who

respond inadequately to oral drugs or for whom they are

contra-indicated.






http://publications.nice.org.uk/fluocinolone-acetonide-intravitreal-implant-for-treating-chronic-diabetic-macular-oedema-after-an-ta301
































http://publications.nice.org.uk/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration-ta294

http://publications.nice.org.uk/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration-ta294

http://guidance.nice.org.uk/ta155


















Overactive bladder - mirabegron (TA290) 30/06/2013 Mirabegron – recommended as possible treatment for

overactive bladder if antimuscarinics are ineffective,

contra-indicated, or not tolerated.

x17/07/2013 17

Myelofibrosis (splenomegaly, symptoms) -

ruxolitinib (TA289)

30/06/2013 Ruxolitinib – not recommended for people with an

enlarged spleen or symptoms from myelofibrosis.x


Type 2 diabetes - Dapagliflozin combination

therapy (TA288)

30/06/2013 Dapagliflozin – recommended as possible treatment: (1)

with metformin if used as NICE recommends gliptins in

CG87; (2) with insulin (with or without other antidiabetic

drugs). To be used with metformin and sulfonylurea only

in a clinical trial.

x

19/08/2013 50

Pulmonary embolism and recurrent venous

thromboembolism - rivaroxaban (TA287)

30/06/2013 Rivaroxaban – recommended as possible treatment for

PE, and to prevent recurrent DVT or PE.x

02/07/2013 2

Schizophrenia or bipolar disorder - loxapine

inhalation (terminated appraisal) (TA286)

31/05/2013 Loxapine – unable to recommend NHS use for acute

agitation and disturbed behaviours in schizophrenia and

bipolar disorder, because no evidence submission was

received from the manufacturer.

x


Ovarian, fallopian tube and primary peritoneal

cancer (recurrent advanced, platinum-sensitive

or partially platinum-sensitive) - bevacizumab

(TA285)

31/05/2013 Bevacizumab – not recommended with gemcitabine and

carboplatin for first recurrence that has not been

previously treated with bevacizumab or other vascular

endothelial growth factor inhibitors.

x


Bevacizumab in combination with paclitaxel and

carboplatin for first-line treatment of advanced

ovarian cancer (TA284)

31/05/2013 Bevacizumab – not recommended with paclitaxel and

carboplatin (includes fallopian tube and primary

peritoneal cancer).

x


Macular oedema (retinal vein occlusion) -

ranibizumab (TA283)

31/05/2013 Ranibizumab – recommended as possible treatment as

part of a patient access scheme: for central retinal vein

occlusion; or for branch retinal vein occlusion if laser

ineffective or unsuitable.

x

29/07/2013 59

Idiopathic pulmonary fibrosis - pirfenidone

(TA282)

30/04/2013 Pirfenidone – recommended as possible treatment for

patients with FVC between 50% and 80% of expected.

Stop if disease worsens.

x30/07/2013 91 likely to used only following recommendation from

tertiary centre

Gout - canakinumab (terminated appraisal)

(TA281)

30/04/2013 Canakinumab – unable to recommend NHS use because

no evidence received from manufacturer.x


Rheumatoid arthritis - abatacept (2nd line)

(rapid review of TA234) (TA280)

30/04/2013 Abatacept – recommended with methotrexate as

possible treatment option if ‘highly active’ condition and

methotrexate and one other DMARD not effective.

Review 6-monthly for continued efficacy.

x

30/06/2013 61

Asthma (severe, persistent, patients aged 6+,

adults) - omalizumab (rev TA133, TA201)

(TA278)

30/04/2013 Omalizumab – recommended as possible additional

treatment to standard therapy for some people aged 6

years and over with severe persistent allergic asthma

who need continuous or frequent oral steroids.

x


tertiary centre

29 0


implement time

(days)













http://guidance.nice.org.uk/CG87/QuickRefGuide/pdf/English
















































Developed for the NHS by: East and South East England


This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.

All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.


Date of TA

Release


medical condition, as indicated by NICEYes

(mark 'x' if

applicable)

N/A

(mark 'x' if

applicable)

Date of local

decision

(DD/MM/YYYY

)

Time to

implement

(days)


2012-13

Methylnaltrexone for treating opioid-induced

bowel dysfunction in people with advanced

illness receiving palliative care (terminated

appraisal) (TA277)

31/03/2013 Methylnaltrexone – unable to recommend NHS use for

treating opioid-induced bowel dysfunction in people with

advanced illness receiving palliative care because no

evidence submission was received from the

manufacturer.

x

31/03/2013 0 remains available on formulary for named patient

cases

Cystic fibrosis (pseudomonas lung infection) -

colistimethate sodium and tobramycin (TA276)

31/03/2013 Tobramycin and colistimethate sodium dry powders for

inhalation – recommended as possible treatments for

chronic pseudomonas lung infection in some people with

cystic fibrosis, only as part of agreed patient access

schemes. NB At time of publication, implementation

guidance applies only to tobramycin as colistimethate is

not available.

x


tertiary centre

Macular oedema (diabetic) - ranibizumab

(TA274). Review of TA 237

28/02/2013 Ranibizumab – possible treatment for problems with

sight due to diabetic macular oedema if the eye has a

central retinal thickness of 400 micrometres or more at

the start of treatment, only as part of an agreed patient

access scheme.

x

26/03/2013 26

Stroke and systemic embolism (prevention, non-

valvular atrial fibrillation) - apixaban (TA275)

28/02/2013 Apixaban – recommended as a option for prevention of

stroke and systemic embolism in people with atrial

fibrillation and one or more risk factors, but without

underlying heart valve disease.

x

28/02/2013 0

Diabetic macular oedema - fluocinolone

acetonide intravitreal implant (TA271)

31/01/2013 Fluocinolone acetonide impant – Not recommended

when other treatments have not worked well enough.x


Urothelial tract carcinoma (transitional cell;

advanced or metastatic) - vinflunine (TA272)

31/01/2013 Vinflunine – Not recommend for this cancer if treated

previously with platinum-containing drugs.x


Hyperplasia (benign prostatic) - tadalafil

(terminated appraisal) (TA273)

31/01/2013 Tadalafil – unable to recommend NHS use because no

evidence received from manufacturer.x


Melanoma (BRAF V600 mutation positive,

unresectable or metastatic) - vemurafenib

(TA269)

31/12/2012 Vemurafenib – recommended for this indication only as

part of agreed patient access scheme. x21/01/2013 21 available via CDF

Leukaemia (acute myeloid ) - decitabine


31/12/2012 Decitabine – unable to make recommendation about

NHS use due to lack of evidence submission.x










































Melanoma (stage III or IV) - ipilimumab (TA268) 31/12/2012 Ipilimumab – recommended option after prior therapy

for advanced melanoma (unresectable or metastatic),

only as part of agreed patient access scheme.x


Chronic heart failure - ivabradine (TA267) 30/11/2012 Ivabradine – recommended option for stable chronic

heart failure after 4 weeks of optimised standard drugs

alone if heart function meets stated parameters. Given

with standard drugs, or instead of beta blockers if not

tolerated.

x

28/02/2013 90

Cystic fibrosis - mannitol dry powder for

inhalation (TA266)

30/11/2012 Mannitol dry powder for inhalation – recommended

option for cystic fibrosis if rhDNase or other osmotic

drugs are inappropriate, and lung function is rapidly

declining.

x


tertiary centre

Bone metastases from solid tumours -

denosumab (TA265)

31/10/2012 Denosumab – a recommended option instead of a

bisphosphonate for preventing skeletal-related events

caused by bone metastases from solid tumours. Not

recommended for bone metastases from prostate

cancer.

x

17/01/2013 78

Stroke (acute, ischaemic) - alteplase (TA264) 25/09/2012 Alteplase – a recommended option within 4.5 hours of

an acute ischaemic stroke if imaging shows no

haemorrhage.

x

18/10/2012 23

Bevacizumab in combination with capecitabine

for the first-line treatment of metastatic breast

cancer (TA263)

22/08/2012 Bevacizumab with Capecitabine – not recommended

when other chemotherapy (inc. taxanes, anthracyclines)

is not appropriate, or if taxanes or anthracyclines given in

past 12mths.

x


Venous thromboembolism (treatment and long

term secondary prevention) - rivaroxaban

(TA261)

23/07/2012 Rivaroxaban – a recommended option for treating DVT,

and to help prevent a pulmonary embolism or another

DVT.

x

03/09/2012 42

Ulcerative colitis (moderate to severe, second

line) - adalimumab (TA262)

26/07/2012 Adalimumab – unable to recommend NHS use. TA

terminated due to lack of evidence submission.x


Breast cancer (metastatic hormone-receptor) -

lapatinib and trastuzumab (with aromatase

inhibitor) (TA257)

04/07/2012 Lapatinib & trastuzumab – not recommended with an

aromatase inhibitor for post-menopausal women with

HER2 and hormone receptor positive metastatic breast

cancer.

x


Migraine (chronic) - botulinum toxin type A

(TA260)

26/06/2012 Botulinum toxin – a recommended option for preventing

headaches in some adults with chronic migraine. x31/08/2012 66

Prostate cancer (metastatic, castration

resistant) - abiraterone (following cytotoxic

therapy) (TA259)

20/06/2012 Abiraterone – a recommended option for metastatic

prostate cancer after testosterone reduction therapy and

docetaxel.

x14/08/2012 55

Lung cancer (non small cell, EGFR-TK mutation

positive) - erlotinib (1st line) (TA258)

15/06/2012 Erlotinib – a recommended first-line option in locally

advanced or metastatic non-small-cell lung cancer. x14/08/2012 60

Atrial fibrillation (stroke prevention) -

rivaroxaban (TA256)

24/05/2012 Rivaroxaban – a recommended option for atrial

fibrillation patients with risk factors.x

10/07/2012 47

Prostate cancer - cabazitazel (TA255) 15/05/2012 Cabazitaxel – not recommended for patients with

hormone refractory, metastatic prostate cancer who

have had docetaxel.

x


























































Hepatitis C (genotype 1) - telaprevir (TA252) 14/05/2012 Telaprevir – recommended with peginterferon and

ribavirin in compensated liver disease in untreated

patients, or those unresponsive to previous interferon

treatments.

x

16/05/2012 2 likely to used only following initiation by regionally

approved tertiary centre

Hepatitis C (genotype 1) - boceprevir (TA253) 14/05/2012 Boceprevir – recommended with peginterferon and

ribavirin in compensated liver disease in untreated

patients, or those unresponsive to previous treatment.x

16/05/2012 2 likely to used only following initiation by regionally

approved tertiary centre

Multiple sclerosis (relapsing-remitting) -

fingolimod (TA254)

27/04/2012 Fingolimod – recommended for patients not responding

sufficiently to beta interferon.x

29/06/2012 63

Leukaemia (chronic myeloid, first line) -

dasatanib, nilotinib and standard-dose imatinib

(TA251)

24/04/2012 For first-line treatment of chronic phase Philadelphia-

chromosome-positive CML:

Imatinib – recommended as an option.

Nilotinib – recommended as an option only under a

patient access scheme.

x

21/05/2012 27

Breast cancer (advanced) - eribulin (TA250) 15/04/2012 Eribulin – not recommended if cancer progressed despite

two or more chemotherapy regimens.x


27 0


implement time

(days)























This spreadsheet enables self-audit of a medicines formulary for adherence to NICE Technology Appraisals. No copyright is asserted if used for non-commercial purposes within the NHS.


Date of TA

Release


medical condition, as indicated by NICE

Yes N/A Date of local

decision

(DD/MM/YYYY)

Time to

implement

(days)


2011-12

Atrial fibrillation - dabigatran etexilate (TA249) 31/03/2012 Dabigatran – a recommended option for atrial fibrillation

patients with risk factors to prevent stroke and

embolism.

x16/04/2012 16

Rheumatoid arthritis - tocilizumab (TA247)

Update to TA198

29/02/2012 Tocilizumab (with methotrexate) – a recommended

option (in the same circumstances as TA130) after other

specified treatments have failed or not been tolerated.x

02/03/2012 2

Diabetes (type 2) - exenatide (prolonged

release) (TA248)

29/02/2012 Exenatide prolonged release – a recommended option in

combination with oral drugs for selected patients with

type 2 diabetes

x31/05/2012 92

Venom anaphylaxis - immunotherapy

pharmalgen (TA246)

29/02/2012 Pharmalgen – a recommended treatment for bee or

wasp venom allergy after a severe reaction, or moderate

reaction in certain circumstances.

x29/02/2012 0 will not be using locally - available through referral to

specialist centre

Venous thromboembolism (hip and knee

surgery) - apixaban (TA245)

31/01/2012 Apixaban – a recommended option to reduce

thromboembolism after knee/hip replacement.x

30/04/2012 90

Chronic obstructive pulmonary disease -

roflumilast (TA244)

31/01/2012 Roflumilast – only recommended as part of a clinical

trial.x


Colorectal cancer (metastatic) 2nd line -

cetuximab, bevacizumab and panitumumab

(TA242)

Review of TA150 and part review of TA118

31/01/2012 Cetuximab – not recommended alone or in combination.

Bevacizumab – not recommended with

fluoropyrimidines.

Panitumumab – not recommended.

x


Follicular lymphoma - rituximab (TA243)

Update to TA110

31/01/2012 Rituximab – recommended in combination for first line

treatment of stage III–IV disease.x

23/04/2012 83

Leukaemia (chronic myeloid) - dasatinib,

nilotinib, imatinib (intolerant, resistant) (TA241)

31/01/2012 Dasatinib – not recommended.

Nilotinib – recommended for Philadelphia-chromosome-

positive CML if standard dose imatinib unsuccessful or

unsuitable.

Imatinib high dose – not recommended if disease has

progressed after standard dose.

x

23/04/2012 83

Arthritis (juvenile idiopathic, systemic) -

tocilizumab (TA238)

31/12/2011 Tocilizumab – recommended if NSAIDs, steroids and

methotrexate have failed.x

31/01/2012 31










































Breast cancer (metastatic) - fulvestrant (TA239) 31/12/2011 Fulvestrant – not recommended post-menopause in

oestrogen dependent metastatic disease, or if disease

returned/worsened after anti-oestrogens.x


Colorectal cancer (metastatic) - panitumumab


31/12/2011 Panitumumab – unable to recommend NHS use. TA

terminated due to lack of evidence submission. x31/03/2012 91 will not be using locally

Macular oedema (diabetic) - ranibizumab

(TA237) Replaced by TA274

30/11/2011 Ranibizumab – not recommend for people with diabetic

macular oedema.x


Osteosarcoma - mifamurtide (TA235) 31/10/2011 Mifamurtide – recommended as a treatment for

specified children, adolescents and young adults with

osteosarcoma.

x31/01/2012 92

Acute coronary syndromes - ticagrelor (TA236) 31/10/2011 Ticagrelor – recommended combined with low-dose

aspirin for up to a year as a treatment for specified

people with acute coronary syndromes.

x23/12/2011 53

Ankylosing spondylitis - golimumab (TA233) 31/08/2011 Golimumab – a recommended option for severe, active

ankylosing spondylitis in the same circumstances as

TA143 when NSAIDs unsuccessful.x

30/11/2011 91

Rheumatoid arthritis - abatacept (2nd line)

(TA234)

31/08/2011 Abatacept – not recommended with methotrexate in

moderate to severe RA if DMARDs ineffective. x30/11/2011 91 will not be using locally

Macular oedema (retinal vein occlusion) -

dexamethasone (TA229)

31/07/2011 Dexamethasone intravitreal implant – recommended

for specified people with macular oedema due to retinal

vein occlusion.

x31/10/2011 92

Depression - agomelatine (terminated appraisal)

(TA231)

31/07/2011 Agomelatine – unable to recommend NHS use for major

depressive episodes. TA terminated due to lack of

evidence submission.


Epilepsy (partial) - retigabine (adjuvant) (TA232) 31/07/2011 Retigabine – a recommended adjunctive option for

partial onset seizures with or without secondary

generalisation in some people with epilepsy.x

31/10/2011 92

Multiple myeloma (first line) - bortezomib and

thalidomide (TA228)

31/07/2011 Thalidomide – a recommended option for specified

people with multiple myeloma.

Bortezomib – a recommended option only if thalidomide

not tolerated or suitable.

x

31/10/2011 92

Myocardial infarction (persistent ST-segment

elevation) - bivalirudin (TA230)

31/07/2011 Bivalirudin – recommended as a possible treatment for

adults with STEMI having percutaneous coronary

intervention.

x31/10/2011 92

Lung cancer (non-small-cell, advanced or

metastatic maintenance treatment) - erlotinib

(monotherapy) (TA227)

30/06/2011 Erlotinib – not recommended as maintenance after

platinum-chemotherapy. x30/09/2011 92 available via CDF

Lymphoma (follicular non-Hodgkin's) - rituximab

(TA226)

30/06/2011 Rituximab – recommended as a possible treatment to

maintain remission.x

30/09/2011 92

Rheumatoid arthritis (after failure of previous

anti-rheumatic drugs) - golimumab (TA225)

30/06/2011 Golimumab – a recommended option (in the same

circumstances as TA130) after other specified treatments

have failed or not been tolerated.x

30/09/2011 92

Rheumatoid arthritis (methotrexate-naïve) -

golimumab (terminated appraisal) (TA224)

30/06/2011 Golimumab – unable to recommend NHS use. TA

terminated due to lack of evidence submission. x






























































Peripheral arterial disease - cilostazol,

naftidrofuryl oxalate, pentoxifylline and inositol

nicotinate (TA223)

31/05/2011 Naftidrofuryl oxalate – a recommended option for

intermittent claudication in peripheral arterial disease.

Cilostazol, pentoxifylline and inositol nicotinate – not

recommended.

x

31/08/2011 92

Thrombocytopenic purpura - romiplostim

(TA221)

30/04/2011 Romiplostim – recommended for specified people with

chronic, severe, and refractory ITP.x

28/06/2011 59

Ovarian cancer (relapsed) - trabectedin (TA222) 30/04/2011 Trabectedin – not recommended with pegylated

liposomal doxorubicin for relapsed platinum-sensitive

ovarian cancer.


Psoriatic arthritis - golimumab (TA220) 30/04/2011 Golimumab – recommended as a possible treatment

after trying other DMARDs in the same circumstances as

TA199.

x27/06/2011 58

Everolimus for the second-line treatment of

advanced renal cell carcinoma (TA219)

30/04/2011 Everolimus – not recommended.x


31 0


implement time

(days)


























Date of TA

Release




decision

(DD/MM/YYYY)

Time to

implement

(days)


2010-11

Alzheimer's disease - donepezil, galantamine,

rivastigmine and memantine (TA217)

31/03/2011 Donepezil, galantamine, rivastigmine – recommended

options for mild and moderate disease.

Memantine – a recommended option for moderate

disease if people cannot take AChE inhibitors, and for

managing severe disease.

x

30/06/2011 91

Myelodysplastic syndromes - azacitidine (TA218) 31/03/2011 Azacitidine – a recommended option for specified adults

not eligible for haematopoietic stem cell transplantation. x30/06/2011 91

Renal cell carcinoma (first line metastatic) -

pazopanib (TA215)

28/02/2011 Pazopanib – a recommended option for some people

with renal cell carcinoma.x

31/05/2011 92

Breast cancer - bevacizumab (in combination

with a taxane) (TA214)

28/02/2011 Bevacizumab – not recommended with a taxane first line

for metastatic breast cancer.x


Leukaemia (lymphocytic) - bendamustine

(TA216)

28/02/2011 Bendamustine – a recommended option for untreated

chronic lymphocytic leukaemia of Binet stage B or C

where fludarabine cannot be used.

x

31/05/2011 92

Schizophrenia - aripiprazole (TA213) 31/01/2011 Aripiprazole – a recommended option in 15 to 17 year

olds with schizophrenia if risperidone unresponsive/

unsuitable.x

30/04/2011 89 will not be initiating locally (unless recommended by

mental health specialist)

Osteoporosis - primary prevention (TA160) 31/01/2011 As an option to prevent fractures in postmenopausal

women with osteoporosis but no fractures:

Alendronate – recommended.

Risedronate, etidronate – recommended if alendronate

not suitable.

Strontium ranelate – recommended if bisphosphonates

not suitable.

Raloxifene – not recommended

x

30/04/2011 89



























Osteoporosis - secondary prevention including

strontium ranelate (TA161)

31/01/2011 As an option to prevent fractures in postmenopausal

women with osteoporosis who have had fractures:

Alendronate – recommended.

Risedronate, etidronate – recommended if alendronate

not suitable.

Strontium ranelate, raloxifene – recommended if

bisphosphonates not suitable.

Teriparatide – If above options not suitable, or fracture

sustained while on bisphosphonates.

x

30/04/2011 89

Constipation (women) - prucalopride (TA211) 31/12/2010 Prucalopride – recommended as an option for women

with chronic constipation after failure of high dose

laxatives.

x31/03/2011 90

Vascular disease - clopidogrel and dipyridamole

(TA210)

31/12/2010 As an option to prevent occlusive vascular events:

Clopidogrel – recommended after ischaemic stroke; in

peripheral arterial/ multivascular disease; or after MI

only if aspirin not suitable.

Dipyridamole m/r with aspirin – recommended after a

TIA; or after an ischaemic stroke only if clopidogrel

unsuitable.

Dipyridamole m/r alone – recommended after an

ischaemic stroke if aspirin and clopidogrel unsuitable; or

after a TIA if aspirin unsuitable.

x

31/03/2011 90

Colorectal cancer (metastatic) - bevacizumab

(TA212)

31/12/2010 Bevacizumab – not recommended with oxaliplatin and

either fluorouracil plus folinic acid, or capecitabine. x


Gastric cancer (HER2-positive metastatic) -

trastuzumab (TA208)

30/11/2010 Trastuzumab – recommended as possible first line

treatment for specified types of HER2-positive metastatic

gastric adenocarcinoma.

x

28/02/2011 90

Gastrointestinal stromal tumours

(unresectable/metastatic) - imatinib (TA209)

Part update to TA86

30/11/2010 Imatinib – not recommended at higher doses if

unresectable and/or metastatic GISTs progress, despite

imatinib 400 mg a day. See also TA86.x


Diabetes (type 2) - liraglutide (TA203) 31/10/2010 Liraglutide – a recommended option at a dose of 1.2 mg

daily and no more, with specified oral therapy. x

31/01/2011 92

Osteoporotic fractures - denosumab (TA204) 31/10/2010 Denosumab – a recommended option for primary and

secondary prevention of fractures in postmenopausal

women with osteoporosis if oral bisphosphonates not

suitable.

x

31/01/2011 92

Asthma (in children) - omalizumab (TA201) 31/10/2010 Omalizumab – not recommended for children aged 6 to

11 years with severe persistent allergic asthma. x31/01/2011 92 will not be using locally

Chronic lymphocytic leukaemia - ofatumumab

(TA202)

31/10/2010 Ofatumumab – not recommended for chronic

lymphocytic leukaemia refractory to fludarabine and

alemtuzumab.


Lymphoma (non-Hodgkin's) - bendamustine


31/10/2010 Bendamustine – unable to recommend NHS use. TA

terminated due to lack of evidence submission. x











































Mantle cell lymphoma (relapsed) - temsirolimus


31/10/2010 Temsirolimus – unable to recommend NHS use. TA


Thrombocytopenic purpura - eltrombopag

(TA205)

31/10/2010 Eltrombopag – not recommended for chronic immune

(idiopathic) thrombocytopenic purpura.x


Hepatitis C - peginterferon alfa and ribavirin

(TA200)

30/09/2010 Peginterferon alfa (2a or 2b) plus ribavirin – partial

update to TA75 and TA106 to broaden the indications for

treatment.

x

31/12/2010 92

Rheumatoid arthritis - drugs for treatment after

failure of a TNF inhibitor (TA195)

Replaces TA36,TA126,TA141

31/08/2010 Rituximab – a recommended option with methotrexate,

if inadequate response or intolerance to other DMARDs

including at least one TNF inhibitor.

Adalimumab, etanercept, infliximab, abatacept –

recommended options, with methotrexate, if rituximab

contraindicated or not tolerated.

Adalimumab, etanercept – recommended monotherapy

options if rituximab cannot be given because

methotrexate contraindicated or not tolerated.

x

30/11/2010 91

Psoriatic arthritis - etanercept, infliximab and

adalimumab (TA199)

Replaces TA104, TA125

31/08/2010 Etanercept, infliximab, adalimumab – recommended for

active & progressive psoriatic arthritis, based on specific

criteria. Use the least expensive.x

30/11/2010 91

Atrial fibrillation - dronedarone (TA197) 31/08/2010 Dronedarone – a recommended option for some people

with non-permanent atrial fibrillation. x30/11/2010 91

Gastrointestinal stromal tumours - imatinib

(adjuvant) (TA196)

31/08/2010 Imatinib – not recommended as adjuvant treatment

after surgical removal of a GIST.x


Lung cancer (non-small-cell, first line) - gefitinib

(TA192)

31/07/2010 Gefitinib – a recommended option for first treatment of

EGFR-TK mutation positive locally advanced or metastatic

non-small-cell lung cancers.x

31/10/2010 92

Bone loss (therapy-induced) in non-metastatic

prostate cancer - denosumab (terminated

appraisal) (TA194)

31/07/2010 Denosumab – unable to recommend NHS use. TA


Gastric cancer (advanced) - capecitabine

(TA191)

31/07/2010 Capecitabine – recommended with platinum-containing

drugs as a first line option for advanced, inoperable

stomach cancer.x

31/10/2010 92

Leukaemia (chronic lymphocytic, relapsed) -

rituximab (TA193)

31/07/2010 Rituximab – a recommended option with fludarabine and

cyclophosphamide for some people with relapsed or

refractory chronic lymphocytic leukaemia.x

31/10/2010 92

Lung cancer (non-small-cell) - pemetrexed

(maintenance) (TA190)

30/06/2010 Pemetrexed – a recommended maintenance treatment

option for some people with non-small-cell lung cancer. x

30/09/2010 92

Human growth hormone (somatropin) for the

treatment of growth failure in children (review)

(TA188)

Replaces TA42

31/05/2010 Growth hormone (somatropin) – a recommended option

for some children with growth failure.x

31/08/2010 92

























































Hepatocellular carcinoma (advanced and

metastatic) - sorafenib (first line) (TA189)

31/05/2010 Sorafenib – not recommended.x


Crohn's disease - infliximab (review) and

adalimumab (review of TA40) (TA187)

31/05/2010 Infliximab – a recommended option for some people

with severe active/ fistulising disease.

Adalimumab – a recommended option for some people

with severe active disease.

x

31/08/2010 92

33 0


implement time

(days)















Date of TA

Release




decision

(DD/MM/YYYY)

Time to

implement

(days)


2009-10

Rheumatoid arthritis - certolizumab pegol

(TA186)

28/02/2010 Certolizumab pegol – a recommended option for severe

'active' disease if methotrexate and another DMARD

unsuccessful. Usually given with methotrexate, but

monotherapy if methotrexate not tolerated. Use as per

TA130.

x

31/05/2010 92

Soft tissue sarcoma - trabectedin (TA185) 28/02/2010 Trabectedin – a recommended option for advanced

disease where treatment with anthracyclines and

ifosfamide is unsuitable, has failed, or is not tolerated.x

31/05/2010 92

Lung cancer (small-cell) - topotecan (TA184) 30/11/2009 Oral topotecan – a recommended option for relapsed

small-cell lung cancer in specified circumstances.

IV topotecan – not recommended.x

28/02/2010 90

Cervical cancer (recurrent) - topotecan (TA183) 31/10/2009 Topotecan – a recommended option for recurrent or

stage IVB cervical cancer with cisplatin, if cisplatin not

given before. x

31/01/2010 92

Acute coronary syndrome - prasugrel (TA182) 31/10/2009 Prasugrel – a recommended option with aspirin for

patients undergoing PCI in specific circumstances. x

31/01/2010 92

Lung cancer (non-small-cell, first line treatment) -

pemetrexed (TA181)

30/09/2009 Pemetrexed – a recommended first line option for locally

advanced or metastatic adeno-or large-cell carcinoma

types of non-small-cell lung cancer.x

31/12/2009 92

Gastrointestinal stromal tumours - sunitinib

(TA179)

30/09/2009 Sunitinib – a recommended option for unresectable or

metastatic malignant GIST if imatinib unsuccessful or

unsuitable. x

31/12/2009 92

Psoriasis - ustekinumab (TA180) 30/09/2009 Ustekinumab – a recommended option for severe plaque

psoriasis when other treatments unsuccessful or

unsuitable. x

31/12/2009 92

Colorectal cancer (first line) - cetuximab (TA176) 31/08/2009 Cetuximab – recommended in combination with FOLFOX

as first line option for metastatic colorectal cancer in

specific circumstances. Use with FOLFIRI, if FOLFOX

unsuitable.

x

30/11/2009 91

Eczema (chronic) - alitretinoin (TA177) 31/08/2009 Alitretinoin – a recommended option for severe chronic

hand eczema unresponsive to potent topical steroids. x30/11/2009 91



































Renal cell carcinoma (TA178) 31/08/2009 Bevacizumab, sorafenib, temsirolimus – not

recommended first line for advanced and/or metastatic

renal cell carcinoma.

Sorafenib, sunitinib – not recommended second line.

x


Hepatitis B - tenofovir disoproxil fumarate

(TA173)

31/07/2009 Tenofovir disoproxil – a recommended option for

chronic hepatitis B.x

31/10/2009 92

Leukaemia (chronic lymphocytic, first line) -

rituximab (TA174)

31/07/2009 Rituximab – a recommended first line option for chronic

lymphocytic leukaemia only in combination with

fludarabine and cyclophosphamide.x

31/10/2009 92

Lung cancer (non-small-cell, second line) -

gefitinib (terminated appraisal) (TA175)

31/07/2009 Gefitinib – unable to recommend NHS use. TA

terminated due to lack of evidence submission.x


Head and neck cancer (squamous cell

carcinoma) - cetuximab (TA172)

30/06/2009 Cetuximab – not recommended with platinum drugs for

recurrent and/or metastatic squamous cell cancer of the

head and neck.


Multiple myeloma - lenalidomide (TA171) 30/06/2009 Lenalidomide – a recommended option with

dexamethasone for multiple myeloma after failure of two

previous treatments.

x30/09/2009 92

Venous thromboembolism - rivaroxaban

(TA170)

30/04/2009 Rivaroxaban – a recommended option for

thromboembolism prophylaxis arising from elective total

hip or knee replacement surgery. x

31/07/2009 92

17 0


implement time

(days)

































Date of TA

Release




decision

(DD/MM/YYYY)

Time to

implement

(days)


2008-09

Renal cell carcinoma - sunitinib (TA169) 31/03/2009 Sunitinib – a recommended first line option for mobile

people with advanced and/or metastatic disease if

immunotherapy suitable.

x30/06/2009 91

Influenza (treatment) - zanamivir, amantadine

and oseltamivir (review) (TA168)

28/02/2009 Note national guidance on flu jabs.

For flu that is not a widespread epidemic:

Oseltamivir, zanamivir – a recommended option in ‘at

risk’ people in specified circumstances.

Amantadine – not recommended to treat flu.

x

31/05/2009 92

Hyperuricaemia - febuxostat (TA164) 31/12/2008 Febuxostat – recommended option for chronic

hyperuricaemia in gout if allopurinol unsuitable or not

tolerated.

x31/03/2009 90

Ulcerative colitis (acute exacerbations) -

infliximab (TA163)

31/12/2008 Infliximab – a recommended option in severely active

ulcerative colitis if ciclosporin inappropriate, or as part of

a clinical trial.

x31/03/2009 90

Lung cancer (non-small-cell) - erlotinib (TA162) 30/11/2008 Erlotinib – recommended if one previous chemotherapy

regimen ineffective, as cost neutral alternative to

docetaxel. Not recommended in locally advanced or

metastatic NSCLC after one prior unsuccessful regimen

when docetaxel unsuitable. Not recommended after two

prior unsuccessful regimens, including docetaxel.

x

28/02/2009 90

Influenza (prophylaxis) - amantadine,

oseltamivir and zanamivir (TA158) Including

review of TA67

30/09/2008 Note national guidance on flu jabs.

For flu that is not a widespread epidemic:

Oseltamivir, zanamivir – a recommended option in non-

vaccinated, flu-exposed, ‘at risk’ people in specified

circumstances.

Amantadine – not recommended to prevent flu.

x

31/12/2008 92

Venous thromboembolism - dabigatran (TA157) 30/09/2008 Dabigatran etexilate – recommended option to reduce

VTE risk after hip or knee replacement surgery. x31/12/2008 92

Macular degeneration (age-related) -

ranibizumab and pegaptanib (TA155)

31/08/2008 Ranibizumab – a recommended option for

deteriorating wet AMD in specified circumstances.

Pegaptanib – not recommended for wet AMD. x

30/11/2008 91



































Pregnancy (rhesus negative women) - routine

anti-D (review) (TA156)

31/08/2008 Anti-D immunoglobulin – a recommended antenatal

option for RhD negative pregnant women who are not

known to be 'sensitised'.

x

30/11/2008 91

Hepatitis B - telbivudine (TA154) 31/08/2008 Telbivudine – not recommended for chronic hepatitis B.x


Hepatitis B - entecavir (TA153) 31/08/2008 Entecavir – a recommended option for chronic hepatitis

B.x

30/11/2008 91

Head and neck cancer - cetuximab (TA145) 30/06/2008 Cetuximab – a recommended option with radiotherapy

for locally advanced squamous cell disease with

Karnofsky score 90% or more, and if platinum-based

chemotherapy inappropriate.

x

30/09/2008 92

Psoriasis - adalimumab (TA146) 30/06/2008 Adalimumab – a recommended option for severe plaque

psoriasis if other treatments are unsuitable, unsuccessful

or not tolerated.

x30/09/2008 92

Glioma (recurrent) - carmustine implants


30/06/2008 Gefitinib – unable to recommend NHS use as an adjunct

to surgery. TA terminated due to lack of evidence

submission.

x30/09/2008 92

Lung cancer (non-small-cell) - bevacizumab


30/06/2008 Bevacizumab – unable to recommend NHS use with

platinum-based chemotherapy for unresectable non-

small-cell lung cancer (other than predominantly

squamous cell histology). TA terminated due to lack of

evidence submission.

x

30/09/2008 92

Anaemia (cancer-treatment induced) -

erythropoietin (alpha and beta) and darbepoetin

(TA142)

31/05/2008 Erythropoietin analogues with iron injections – a

recommended option for profound anaemia after

chemotherapy if blood transfusions cannot be given; and

after platinum-based chemotherapy for ovarian cancer if

haemoglobin is 8 g/100 ml or less.

x

31/08/2008 92

Ankylosing spondylitis - adalimumab, etanercept

and infliximab (TA143)

31/05/2008 Adalimumab, etanercept – recommended options for

severe ankylosing spondylitis if at least 2 NSAIDs

ineffective. The other drug may be tried if the first is not

tolerated, but not if it is ineffective.

Infliximab – not recommended.

x

31/08/2008 92

Ulcerative colitis (subacute manifestations) -

infliximab (TA140)

30/04/2008 Infliximab – not recommended for subacute, moderate

to severely active ulcerative colitis as specified. x31/07/2008 92 will not be using locally

18 0


implement time

(days)












































Date of TA

Release




decision

(DD/MM/YYYY)

Time to

implement

(days)


2007-08

Chronic asthma (in adults) - corticosteroids

(TA138)

31/03/2008 Inhaled corticosteroids – the least costly suitable product

is recommended when indicated.

Inhaled corticosteroid with long-acting beta-2 agonist –

a combination device is a recommended option; use the

least costly. Separate inhalers may be suitable on an

individual basis.

x

30/06/2008 91

Lymphoma (follicular non-Hodgkin's) - rituximab

(TA137)

Review of TA37

29/02/2008 Rituximab – a recommended option with chemotherapy

to induce remission, or alone as maintenance therapy

during remission. Monotherapy also an option for

relapsed or refractory disease when other options

exhausted.

x

30/05/2008 91

Mesothelioma - pemetrexed disodium (TA135) 31/01/2008 Pemetrexed – a recommended option for specified

people with advanced or unresectable malignant pleural

mesothelioma.

x

30/04/2008 90

Psoriasis - infliximab (TA134) 31/01/2008 Infliximab – a recommended option for severe plaque


or not tolerated.

x30/04/2008 90

Chronic asthma (in children) - corticosteroids

(TA131)

30/11/2007 Inhaled corticosteroids – when indicated, use the least

costly suitable product.

Inhaled corticosteroid with long-acting beta-2 agonist –

when both indicated, a combination device may be used;

use the least costly suitable option.

x

29/02/2008 91

Asthma (uncontrolled) - omalizumab (TA133) 30/11/2007 Omalizumab – recommended option for specified non-

smokers with severe persistent allergic asthma, despite

using other asthma medicines.x

29/02/2008 91

Hypercholesterolaemia - ezetimibe (TA132) 30/11/2007 Ezetimibe – a recommended option for heterozygous-

familial and non-familial hypercholesterolaemia with a

statin if cholesterol not low enough, or as monotherapy if

a statin unsuitable.

x

29/02/2008 91



























Multiple myeloma - bortezomib (TA129) 31/10/2007 Bortezomib – a recommended monotherapy for

progressive multiple myeloma at first relapse after one

prior therapy in people who have undergone, or are

unsuitable for, bone marrow transplant.

x

31/01/2008 92

Rheumatoid arthritis - adalimumab, etanercept

and infliximab (TA130)

Partially updates TA36

31/10/2007 Adalimumab, etanercept, infliximab – recommended

options for rheumatoid arthritis after trying

methotrexate and another DMARD. Usually with

methotrexate, but monotherapy if methotrexate

unsuitable.

x

31/01/2008 92

Lung cancer (non-small-cell) - pemetrexed

(TA124)

(See TA181 for first line use)

31/08/2007 Pemetrexed – not recommended for locally advanced or

metastatic non-small-cell lung cancer after prior

chemotherapy.

x


Multiple sclerosis - natalizumab (TA127) 31/08/2007 Natalizumab – a recommended option for rapidly

evolving severe relapsing-remitting MS.x

30/11/2007 91

Smoking cessation - varenicline (TA123) 31/07/2007 Varenicline – a recommended option for smokers who

want to stop, normally as part of a cessation programme. x31/10/2007 92

Glioma (newly diagnosed and high grade) -

carmustine implants and temozolomide (TA121)

30/06/2007 Carmustine implants – a recommended option for newly

diagnosed high-grade glioma if more than 90% of the

tumour has been removed.

Temozolomide – a recommended option for newly

diagnosed glioblastoma multiforme in specified

circumstances.

x

30/09/2007 92

Ischaemic stroke (acute) - alteplase (TA122) 30/06/2007 Alteplase – a recommended option for acute ischaemic

stroke.x

30/09/2007 92

14 0


implement time

(days)

































Date of TA

Release




decision

(DD/MM/YYYY)

Time to

implement

(days)


2006-07

Leukaemia (lymphocytic) - fludarabine (TA119) 28/02/2007 Fludarabine – monotherapy not recommended as initial

treatment for chronic lymphocytic leukaemia. x

30/05/2007 91

Breast cancer - gemcitabine (TA116) 31/01/2007 Gemcitabine with paclitaxel – a recommended option

for metastatic breast cancer only when docetaxel

monotherapy or docetaxel plus capecitabine are also

appropriate.

x

30/04/2007 89

Colorectal cancer (metastatic) - bevacizumab

and cetuximab (TA118) (partially updated by

TA242)

31/01/2007 Bevacizumab with 5-fluorouracil plus folinic acid, with

or without irinotecan – not recommended first line.

Cetuximab with irinotecan – not recommended if

previous treatment included irinotecan.

x


Hyperparathyroidism - cinacalcet (TA117) 31/01/2007 Cinacalcet – recommended for people on dialysis with

hyperparathyroidism only if unresponsive to other

treatments or if parathyroidectomy unsuitable. x

30/04/2007 89

Drug misuse - methadone and buprenorphine

(TA114)

31/01/2007 Methadone, buprenorphine (oral) – recommended

options for opioid dependence as part of a support

programme, with supervised administration for at least

the first 3 months.

x

30/04/2007 89 will not be initiating locally - for specialist mental

health

Drug misuse - naltrexone (TA115) 31/01/2007 Naltrexone – a recommended option for opioid

dependent people who have stopped opioids, but are

highly motivated to stay free from the drugs in an

abstinence programme.

x

30/04/2007 89 will not be initiating locally - for specialist mental

health

Breast cancer (early) - hormonal treatments

(TA112)

30/11/2006 Anastrozole, exemestane, letrozole – recommended

adjuvant options after surgery for early oestrogen-

receptor-positive breast cancer post-menopause.x

31/01/2007 62

Breast cancer (early) - paclitaxel (TA108) 30/09/2006 Paclitaxel – not recommended for the adjuvant

treatment of women with early node-positive breast

cancer. Updated by CG80

x


Breast cancer (early) - docetaxel (TA109) 30/09/2006 Docetaxel – a recommended adjuvant option with

doxorubicin and cyclophosphamide for early node-

positive breast cancer. Updated by CG80x

31/12/2006 92






























http://www.nice.org.uk/guidance/index.jsp?action=byID&o=12132













Breast cancer (early) - trastuzumab (TA107) 31/08/2006 Trastuzumab – a recommended option for early-stage

HER2-positive breast cancer after surgery,

chemotherapy, and radiotherapy if applicable. Updated

by CG80.

x

30/11/2006 91

Hepatitis C - peginterferon alfa and ribavirin

(TA106)

Extension of TA75 and partially updated by

TA200

31/08/2006 Peginterferon alfa and ribavirin – a recommended

option for mild chronic hepatitis C. If ribavirin is

unsuitable, use peginterferon monotherapy. No

recommendation on use in the under 18s, or after liver

transplant, due to lack of evidence.

x

30/11/2006 91

Psoriasis - efalizumab and etanercept (TA103) 31/07/2006 Etanercept – a recommended option for severe plaque


or not tolerated.

Efalizumab – drug withdrawn.

x

31/10/2006 92

Prostate cancer (hormone-refractory) -

docetaxel (TA101)

30/06/2006 Docetaxel – a recommended option for hormone-

refractory metastatic prostate cancer with Karnofsky

score 60% or more. Not recommended if the disease

recurs after a first course.

x

30/09/2006 92

Colon cancer (adjuvant) - capecitabine and

oxaliplatin (TA100)

30/04/2006 Recommended options after surgery for stage III (Dukes’

C) colon cancer:

Capecitabine – as monotherapy.

Oxaliplatin – with 5-fluorouracil and folinic acid.

x

31/07/2006 92

Renal transplantation - immunosuppressive

regimens for children and adolescents (TA99)

30/04/2006 Basiliximab, daclizumab – consider for induction therapy

with combinations that include ciclosporin.

Tacrolimus – an alternative to ciclosporin for initial

therapy or maintenance.

Mycophenolate mofetil – Only consider when intolerant

of calcineurin inhibitors (ciclosporin-like drugs).

Mycophenolate sodium – not recommended.

Sirolimus – not recommended unless intolerant of

calcineurin inhibitors.

x

31/07/2006 92 will not be using induction therapy locally - for tertiary

centre use

15 0


implement time

(days)





































Date of TA

Release




decision

(DD/MM/YYYY)

Time to

implement

(days)


2000-06

Attention deficit hyperactivity disorder (ADHD) -

methylphenidate, atomoxetine and

dexamfetamine (review) (TA98)

31/03/2006 Methylphenidate, atomoxetine, dexamfetamine –

recommended options for ADHD; if more than one is

appropriate, choose the cheapest.

x

30/06/2006 91

Hepatitis B (chronic) - adefovir dipivoxil and

pegylated interferon alpha-2a (TA96)

28/02/2006 Peginterferon alfa-2a – a recommended first line option

for chronic hepatitis B.

Adefovir dipivoxil – recommended option if

peginterferons unsuccessful or not tolerated. Given as

monotherapy or with lamivudine depending on

lamivudine resistance.

x

30/05/2006 91

Cardiovascular disease - statins (TA94) 31/01/2006 Statin therapy is recommended for adults with specified

clinical evidence of CVD or at specified risk of CVD. x

30/04/2006 89

Ovarian cancer (advanced) - paclitaxel,

pegylated liposomal doxorubicin hydrochloride

and topotecan (review) (TA91)

31/05/2005 Paclitaxel, liposomal doxorubicin, topotecan –

recommended options in advanced disease depending

largely upon platinum sensitivity, resistance, tolerance,

and allergy.

x

31/08/2005 92

Gastrointestinal stromal tumours - imatinib

(TA86) Partially updated by TA209

31/10/2004 Imatinib – recommended first-line for management of

people with KIT (CD117)-positive unresectable and/or

metastatic GISTs.

x

31/01/2005 92

Renal transplantation - immuno-suppressive

regimens (adults) (TA85)

30/09/2004 Basiliximab, daclizumab – consider for induction therapy

with combinations that include ciclosporin.

Tacrolimus – an alternative to ciclosporin for initial

therapy or maintenance.

Mycophenolate mofetil – Only consider when intolerant

of calcineurin inhibitors (ciclosporin-like drugs).

Sirolimus – not recommended unless intolerant of

calcineurin inhibitors.

x

31/12/2004 92 will not be using induction therapy locally - for

transplant centre use only

Atopic dermatitis (eczema) - topical steroids

(TA81)

31/08/2004 Topical corticosteroid – the cheapest suitable option for

atopic eczema should be used and applied no more than

twice daily.x

30/11/2004 91































Atopic dermatitis (eczema) - pimecrolimus and

tacrolimus (TA82)

31/08/2004 Not recommended for first line use or mild disease. If

maximum topical steroids ineffective or threaten

important side effects, consider:

Tacrolimus – for moderate to severe disease in patients

over 2 years.

Pimecrolimus – for moderate disease on face and neck

for those between 2 and 16 years.

x

30/11/2004 91

Insomnia - newer hypnotic drugs (TA77) 30/04/2004 Zaleplon, zolpidem, zopiclone – prescribe the cheapest

of these or a shorter-acting benzodiazepine, for a short

period, if non-drug treatments don’t work. x

31/07/2004 92

Hepatitis C - pegylated interferons, ribavirin and

alfa interferon (TA75)

Partially updated by TA200; replaces TA14

31/01/2004 Peginterferon alfa with ribavirin – recommended for

moderate to severe chronic hepatitis C as specified

within this TA .x

30/04/2004 90

Leukaemia (chronic myeloid) - imatinib (TA70)

(partially updated by TA241 and TA251)

31/10/2003 Imatinib – a recommended option for those who present

in the accelerated phase or with blast crisis, or those in

chronic phase who progress to these stages without prior

imatinib.

x

31/01/2004 92

Macular degeneration (age-related) -

photodynamic therapy (TA68)

30/09/2003 Verteporfin – recommended for wet ARMD in specified

people if classic subfoveal choroidal neovascularisation

(CNV), with no sign of occult CNV. Not recommended for

wet ARMD with mostly classic and some occult CNV

unless in a clinical trial. No recommendation about PDT

for ARMD with occult CNV since product unlicensed.

x

31/12/2003 92

Non-Hodgkin's lymphoma - rituximab (TA65) 30/09/2003 Rituximab with CHOP – recommended first line for

diffuse large-B-cell lymphoma at stage 2, 3 or 4; in stage

1 only in a clinical trial. Rituximab not recommended

without CHOP.

x

31/12/2003 92

Growth hormone deficiency (adults) - human

growth hormone (TA64)

31/08/2003 Human growth hormone – recommended only where

severe growth hormone deficiency severely affects

quality of life. x

30/11/2003 91

Colorectal cancer - capecitabine and tegafur

uracil (TA61)

30/05/2003 Capecitabine or tegafur with uracil (and folinic acid) –

recommended among first options for metastatic

colorectal cancer.

x31/08/2003 93

Ovarian cancer - paclitaxel (review) (TA55)

Partially updated by TA91

31/01/2003 Cisplatin or carboplatin, with or without paclitaxel –

recommended as alternatives for first-line use (usually

following surgery) in ovarian cancer.x

30/04/2003 89

Diabetes (types 1 and 2) - long acting insulin

analogues (TA53)

31/12/2002 Insulin glargine – a recommended option for type 1

diabetes. Guidance in type 2 diabetes is contained in the

CG66 Update.

x

31/03/2003 90

Myocardial infarction - thrombolysis (TA52) 31/10/2002 Alteplase, reteplase, streptokinase, tenecteplase –

suggestions made on how to choose the most

appropriate agent in hospitals. Reteplase or tenecteplase

recommended for use outside hospitals.

x

31/01/2003 92
















































Acute coronary syndromes - glycoprotein IIb/IIIa

inhibitors (review) (TA47)

Partially updated by CG94

30/09/2002 A GP IIb/IIIa inhibitor should be considered as an elective

PCI adjunct in patients with diabetes, and in patients

undergoing specified complex procedures. Not

recommended in procedurally uncomplicated elective

PCI unless specified complications occur.

x

31/12/2002 92

Arthritis (juvenile idiopathic) - etanercept (TA35) 31/03/2002 Etanercept – recommended for 4–17 year olds with

active disease where methotrexate unsuccessful or not

tolerated.x

30/06/2002 91

Asthma (older children) - inhaler devices (TA38) 31/03/2002 Inhaler choice should reflect patient needs:

Steroids – press-and-breathe inhalers with a spacer

recommended first line.

Bronchodilators – a wider choice of inhalers, including

easily portable ones.

x

30/06/2002 91

Breast cancer - trastuzumab (TA34) 31/03/2002 In metastatic breast cancer with HER2 at 3+:

Trastuzumab with paclitaxel – recommended if no prior

chemo and anthracyclines inappropriate.

Trastuzumab monotherapy – recommended after at

least two other regimens tried including at least one

anthracycline, taxane, and hormonal treatment if

appropriate.

x

30/06/2002 91

Multiple sclerosis - beta interferon and

glatiramer acetate (TA32)

31/01/2002 Beta interferon, glatiramer – recommendation to use

these medicines not justified. x30/04/2002 89

Leukaemia (lymphocytic) - fludarabine (TA29) 31/01/2002 Fludarabine – recommended option orally instead of

CHOP, VAP or CVP regimens in B-cell CLL if first chemo

regimen unsuccessful or not tolerated. Use infusion only

if oral route not suitable.

x

30/04/2002 89

Pancreatic cancer - gemcitabine (TA25) 30/05/2001 Gemcitabine – a first line option for advanced or

metastatic disease if Karnofsky score 50 or more, if

curative surgery not an option. Not for second line use.x

31/08/2001 93

Brain cancer - temozolomide (TA23) 30/04/2001 Temozolomide – consider for specified people with

recurrent brain cancer if initial chemo failed or not

tolerated. Only for first line use in a clinical trial.x

31/07/2001 92

Motor neurone disease - riluzole (TA20) 31/01/2001 Riluzole – should be available for MND. x 30/04/2001 89

Asthma (children under 5) - inhaler devices

(TA10)

31/08/2000 Steroids, bronchodilators – deliver by a pressurised

metered dose inhaler with spacer, using a facemask if

necessary. If this not suitable, consider a nebuliser, or a

dry powder inhaler in the over 3s.

x

30/11/2000 91

28 0


implement time

(days)




































NICE Technology Appraisals About Medicines: Southend University

Documents

Transcript of NICE Technology Appraisals About Medicines: Southend University